Closest vote: 🐶 versus 🐈🤷🏽‍♂️ Cleanest/unanimous vote: POCUS Our choices where #BlueRibbonFail is most likely: C3G (Dx over Rx) or Trolls (BKV over CMV) #NephMadness

B cell therapies in IgAN advance: povetacicept from Vertex www.medscape.com/s/viewarticl... #NephMadness timing was perfect for this Atacicept has competition now (and there’s the Chinese Telitacicept)

The first #NephMadness commentary lands - and it suggests POCUS in AKI from Dr POCUS himself ajkdblog.org/2026/03/10/n... Which makes me think the Ottawa choice of POCUS in ESRD is right 🤔 though Anna Burgner plays 4D chess 😳

Omega-3 may increase bleeding risk Probably safe when no procedure is planned, but less reassuring in high⚠️ biopsy patients, issue still under study. If injecting therapies directly into the renal cortex, I would likely avoid omega-3 to reduce any issue #nephjc pmc.ncbi.nlm.nih.gov/articles/PMC...

🧪 Episode 11: The C3G Revolution Hosts @kdjhaveri.bsky.social & Koyal Jain join @nephrosparks.bsky.social & Duke Fellow Dr. Aarushi Varshney to discuss the shifting landscape of C3G. - The "Two Orders of Magnitude" Rule - Breaking down APPEAR & VALIANT trials Listen: share.transistor.fm/s/72477cca

💥🎙️ Its a DOUBLE FEATURE: GN in Ten x @nephmadness.bsky.social The wait is over. We’re dropping two high-powered episodes to get your brackets ready. Whether you're fighting autoantibodies or the complement cascade, our experts have the breakdown you need! 🦸‍♂️🦸‍♀️ @nkf-professionals.bsky.social #ISGD

Thank you #NephJC 2025-26 interns. You’re da best

Please vote for the #NephJC kidneys! 🏆 Sign up for the newsletter to get a ballot. 2026 #NephJCKidneys vote begins — NephJC

As much as I love kidney biopsies, still believe we can maximize nephroprotective 💊. So many Q for the phase 3 RCT #nephjc

T3q Great discussion! #NephJC Do you think we are entering the era of remission, and dare I say it, cures for chronic kidney disease. Slowing progression is great, but regenerative treatments are the future! #NephJC

If you want to stay on top of #NephJC happenings, sign up for our once-a-week newsletter. www.nephjc.com/newsl...#NephJC

T3l Various studies are in the pipeline; some are completed, some are recruiting, and the majority of the studies are in the US. #NephJC

Biopsies are not totally benign #NephJC 1:100 PRBC 1:1000 Intervention (coil) 1:10,000 Nephrectomy

T2f AND..Reduced 5 yr KFRE risk. #NephJC At mo 18 after the first injection was: Cohort 1: ⬇️29% Cohort 2: ⬇️28% Have you seen this trend with other GDMTs?

T3c Are you not impressed?! #NephJC The findings of the study were significant, and the effect size was substantially larger than the approximately 1.2 mL/min/1.73 m² per year benefit observed with established therapies like SGLT2 inhibitors and GLP-1 RAs in large-scale trials. 🤯

T3j Current research is limited by a selection of pts at different CKD stages & different etiologies. Only a few trials, such as the REACT studies, specifically target DKD. Distinct types of kidney damage may affect the efficacy of the treatment. #NephJC

Check out the insightful summary by me and my co-intern. Dr. Sai Vani Dr SaiVani Yellampalli #NephJC Dr Akshaya Akshaya Jayachandran

🎨 Beautiful visual abstract by Dr Natalia Nombera Natalia Nombera Aznaran #NephJC

Before we start, take a look at the article itself. Have any of the authors seen it? #NephJC pubmed.ncbi.nlm.nih....#NephJC

T0a Cellular therapy is an emerging investigational approach that utilizes patient-derived cells to target multiple maladaptive pathways simultaneously with the potential to preserve organ function…including kidney function! #NephJC

T0b Since 2015, research has demonstrated the efficacy of autologous cell transplantation in tissue regeneration. In addition, animal models showed that these injections halt NfKB & TGF-ꞵ signals, decreasing inflammation driven progressive damage. Win-Win. #NephJC

T0f 👏 A promising phase 1b/2a with type 2 diabetes and moderate CKD with allogeneic mesenchymal precursor cells was safe and well tolerated with a trend to stabilized eGFR. However, getting the right cells to the right place can be challenging. #NephJC

T0g What if we could take out the differentiation and placement issues? What if we could harvest pre-existing kidney cells to repair the kidney? What if we could just inject these cells directly into the kidney? 🤔We have a minimally invasive way to get kidney cells through renal biopsy… #NephJC

T0h The problem with dialysis is that it can handle the filtration of fluid and waste, but it does not replicate the paracrine/endocrine function of the kidney. This is why the replacement of renal parenchymal cells is an attractive therapy at many CKD stages. #NephJC

T1a 📋 This was a phase 2, multicenter, randomized, open-label trial designed to evaluate the safety and efficacy of rilparencel in adults with type 1 or type 2 diabetes mellitus and advanced CKD. #NephJC

T1b Rilparencel- an autologous cell therapy that is composed of cells obtained by kidney biopsy. The harvested tissue undergoes enzymatic digestion & density gradient separation to isolate a heterogeneous population of renal epithelial lineage cells. #NephJC

Listen to this #NephMadness episode of @febrilepodcast.com featuring @drflashheart.bsky.social, @beanbuddy.bsky.social, Sam Kant, @germatologist.bsky.social, and @ssfarouk.bsky.social as they chat about the Trolls of Transplantation Region: player.captivate.fm/episode/b11c...

It's March, and NephMadness is back! Check out the single-elimination tournament of nephrology concepts meant to spark conversation in the online nephrology community. Read more in #ASNKidneyNews and tag #NephMadness on social platforms: kidney.pub/KN1803-04 Matthew Sparks#ASNKidneyNews

▶️ https://youtu.be/-uE52jo8X4A When is #ADH still ⬆️ in #hyponatremia? Low #EABV overrides osmotic suppression via baroreceptor signaling 🧠 ADH physiology 💧 Hyponatremia 🔬 For immersive educational experience www.abckidney.com#ADH#hyponatremia?#EABV#RenalPhysiology #NephSky #MedEd #FOAMed

We're discussing 💉REACT- renal autologous cell treatments (rilprencel) in diabetic kidney disease. Is regenerative medicine the future of nephrology❓ Come discuss 3/10/26 at 9pm #NephJC #NephSky Blog by @drsaivani.bsky.social and @nephromommy-akshu.bsky.social www.nephjc.com/news/rilprencel-react

Will renal autologous cell treatments (REACT) unlock the secret to kidney regenerative medicine? #NephJC #NephSky Come discuss 3/10/26 at 9pm EST Check out the VA by @roxnonna23.bsky.social www.nephjc.com/news/2026/3/9/react-the-visual-abstract

Great to see the fantastic nephrology podcast community highlighted by #NephMadness 👍 French-speaking listeners may also enjoy #NephrOdio, a nephrology education podcast with 630K downloads to date !

#NephMadness is in full swing. Check out the C3G region written by #NephFellow Dr Aarushi Varshney don't forget to submit your brackets! https://ajkdblog.org/2026/03/01/nephmadness-2026-c3g-region/

The #NephMadness IgA Nephropathy region is filled with new advances written by #NephFellow Dr Ale Tomasi Don't forget to fill out your brackets https://ajkdblog.org/2026/03/01/nephmadness-2026-iga-nephropathy-region/

We dove deep into the data for the #NephMadness POCUS Region this year, but let's talk real-world implementation 👴CKD3b 🫁 Septic shock 💧 3 days in, "net even," no edema. On RA 📉 Cr 3.3 ➡️ 4.5. Easy diagnosis of ATN, right? Fluids? Diuretics? Watch and Wait? or #POCUS! 🧵👇

Setting my clock forward five years.

The HIT (Hyponatremia Intervention Trial) is finally out! #hyponatremia #nephrology evidence.nejm.org/doi/10.1056/...

Our new data on subclinical PA and MACE is out in Circulation! For the first time, we show that renin-independant aldosterone production is associated with an increased risk of MACE independently of BP, in people mostly normotensive with low CV risk. www.ahajournals.org/doi/full/10....

#NephMadness 2026 is up and running at https://ajkdblog.org/ Check out all of the content and fill out your brackets https://www.tourneytopia.com/AJKD/NephMadness/default.aspx

It's #NephMadness time!! 👉 ajkdblog.org/2026/03/01/w... #NephJC #NephForward @ajkd.bsky.social

It is #nephmadness time of the year! 🌞Artificial Intelligence in Nephrology-what are the real-world applications and limits? ⭐ Check out our #visualabstracts 👀Read on to know more ajkdblog.org/2026/03/01/n... @nephroseeker.medsky.social @nephrosparks.bsky.social @dramiliflores.bsky.social

#NephMadness 2026: IgA Nephropathy Region Teams: - B-Cell Modulators - Complement Inhibitors Expert: Laura Mariani Writer: Alessandra Tomasi Execs: @nephrosparks.bsky.social & Dia Waguespack bit.ly/NM26IgAN

#NephMadness 2026: AI Region Teams: - Computational Pathology - Natural Language Processing Experts: Lili Chan & Kuang-Yu Jen Writers: Neil Evans & Aditya Yelamanchi Execs: @catochita.bsky.social & @jrkott27.bsky.social bit.ly/NM26AI

“It’s not what you look at that matters, it’s what you see” #POCUS is a non-invasive tool, that allows us to see physiology in motion and track how our treatments transform it in real time. #ER / #CriticalCare have lead the way, but how does it fit in nephrology? #Nephmadness

#NephMadness 2026: Trolls of Transplantation Region Teams: - BK - CMV Experts: Sam Kant & @germatologist.bsky.social Writers: @beanbuddy.bsky.social & @drflashheart.bsky.social Execs: @ssfarouk.bsky.social & @catochita.bsky.social bit.ly/NM26Transplant

#NephMadness 2026: POCUS Region Teams: - POCUS in AKI - POCUS in ESKD Experts: Mohamed Hassan Kamel & Vandana Niyyar Writer: Priyal Sakhuja Execs: @jrkott27.bsky.social & @annaburgner.bsky.social bit.ly/NM26POCUS

#NephMadness 2026: C3G Region Teams: - C3G Diagnosis - C3G Treatment Expert: Bradley Dixon Writer: Aarushi Varshney Execs: @nephrosparks.bsky.social & @kidneywars.bsky.social bit.ly/NM26C3G

#NephMadness 2026: The PodCrawl Featuring these podcasts: - GN in Ten @isgd.bsky.social - Global Kidney Care @theisn.org - @freelyfiltered.bsky.social - @febrilepodcast.com - Kidney Commute @nkf-professionals.bsky.social - @coreimpodcast.bsky.social - Nephron Segment bit.ly/NM26Podcrawl

#NephMadness 2026: Genetics Region Teams: - PKD Masqueraders - Fabry Treatment Expert: Eric Wallace Writers: Steven Clapp & Alyssa Steitz Execs: @annaburgner.bsky.social & @ssfarouk.bsky.social bit.ly/NM26Genetics

#NephMadness 2026: Animal House Region Teams: Dogs vs Cats Experts: Autumn Harris & Kelly Hyndman Writers: Sarah Street & Susan DiGiovanni Execs: @kidneywars.bsky.social & @nephrosparks.bsky.social bit.ly/NM26Animals